It looks easier now because we have a viable product to sell, and a product that we can improve and expand on.
As for date, I wouldn't want to put a date on it, but a few numbers to consider about:
Ellume aims to produce about 250m tests per year
Quidel aims to produce about 600m tests per year
Abbott sold 300m tests in 4th quarter CY in 2020, generated $2.4b of revenue
There are 748m people in Europe, 1.3b people in India, 332m in the US
Around 50m people is affected by Sepsis every year, 11m people dies from it, 1 death every 2.8 seconds
Operon has capacity for 8m completed test per year, and additional 20m strips they can produce
Operon aims to triple its capacity by 2023 (8m x 3 = 24m)
For $5.00 per share, we just need $500m profit (at PE of 20) per year (probably shouldn't use the word 'just', but compare to competitors' numbers, you can see what numbers can be achieved).
ADO Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
